Dr Ranjiv Sivanandan
Head & Neck and Thyroid Surgeon
MBBS (Singapore), FRCS (Edinburgh), MMEd (Surgery), FAMS
Head and neck cancers are the 6th most common cancer worldwide. They consist of a group of biologically similar cancers originating from the upper aero-digestive tract (UADT), which is an anatomic region comprising of the
The majority of head and neck cancers are SQUAMOUS CELL CANCERS (SCC). SCC is strongly associated with lifestyle risk factors, including tobacco and betel nut use, alcohol consumption and certain strains of the human papillomavirus (HPV) that are sexually transmitted.
In the Asian subcontinent a slightly different cancer, NASOPHARYNGEAL CANCER (NPC), also referred to as "NOSE CANCER", is also very common. Although NPC arises from the UADT, it is distinct from squamous cancers of the UADT in its epidemiology, biology, clinical behavior, and treatment.
SCC and NPC often spread to the lymph nodes of the neck, and this is may indeed be the first presentation of the disease, a neck lump representing a swollen cancerous lymph node.
Head and neck cancers are curable if detected early, but treatment frequently involves a combination of surgery, radiation therapy and chemotherapy.
Common symptoms associated with head and neck cancers in are:
Accurate staging of a head and neck cancer is essential for determining the appropriate treatment strategy to adopt as well as for the assessment of long-term prognosis.
The American Joint Committee on Cancer / International Union against Cancer (AJCC/UICC) Staging System is the most universally recognized and accepted staging system. It utilizes the TNM Classification of malignant tumors, where
The T, N, and M scores are then pooled together to provide an overall "stage" of the cancer. Cancer stages range from STAGE I through IV.
Stage I & II are referred to as early stage, and Stage III & IV as advanced stage cancer.
Advancements in diagnostic imaging, surgical techniques and radiation & chemotherapy delivery have led to improvements in survival and quality of life for head and neck cancer patients.
Selection for appropriate treatment strategy for a specific cancer depends on a number of key factors including:
Early stage cancers (Stage I & II) are usually treated with SINGLE MODALITY TREATMENT. This may be in the form of:
Advanced cancers (Stage III & IV) usually require MULTIMODALITY TREATMENT. This may be in the form of:
Early-stage head and neck cancers (Stage I and ll) achieve high cure rates of between 85 - 95%.
More than two thirds of all head and neck cancer patients, unfortunately, present with locally advanced disease. The cure rates for locally advanced disease (Stage Ill and IV) decreases to between 40 - 65%.
Recurrent disease, spread to other organs (metastasis) and new primary cancers are the main cause of morbidity and mortality for head and neck cancers.
\Dr Ranjiv Sivanandan is an accredited general surgeon with a dedicated focus on thyroid and complex head and neck surgery. With over two decades of experience, he has managed a wide range of conditions, including thyroid nodules, thyroid cancer and other head and neck disorders.
Dr Ranjiv is recognised for his expertise in advanced surgical techniques, particularly in robotic thyroid and head and neck surgery. He performed the first robotic thyroidectomy in Singapore and the first robotic neck dissection in Southeast Asia, reflecting his commitment to minimally invasive approaches and surgical innovation. His clinical work is complemented by involvement in research and education, including roles at the National Cancer Centre and the National University of Singapore.
In his clinical practice, Dr Ranjiv adopts a patient-centred approach, ensuring that each individual is fully informed of evidence-based treatment options and actively involved in decision-making. His focus is on delivering personalised care and achieving optimal outcomes for every patient.
3 Mount Elizabeth #17-07
Mount Elizabeth Medical Centre
Singapore 228510